Akums Drugs & Pharmaceuticals Ltd

The company's financial performance is characterized by significant instability and weakness, particularly in profitability. While compounded sales growth has been moderate, recent performance (TTM: 14.32%) is offset by extreme profit volatility. Compounded profit growth figures are misleading due to a low base and erratic annual performance, with TTM profit growth negative at -17%. Annual net profit has fluctuated wildly, from a profit of ₹123 Cr in 2021 to a loss of ₹251 Cr in 2022, followed by a recovery to ₹98 Cr in 2023 and a sharp drop to just ₹1 Cr in 2024. This inconsistency is also reflected in the Operating Profit Margin (OPM), which has been unstable and low in recent years, indicating a lack of control over operational efficiency. The quarterly results further confirm this pattern of erratic sales and profit figures, making financial performance unpredictable.

Capital efficiency and returns are poor and highly inconsistent. The Return on Capital Employed (ROCE) has been extremely volatile, swinging from a respectable 20% in 2021 to a negative -16% in 2022, before rebounding to 22% in 2023 and then collapsing to a mere 2% in the latest year (Mar 2024). This demonstrates an unreliable ability to generate profits from capital invested in the business. Similarly, the Return on Equity (ROE) for the last year stands at 8%, which is a weak return for shareholders. Although the 3-year average ROE is 10%, this is skewed by past performance and does not reflect the current poor state. The Cash Conversion Cycle, while improving in the most recent year to 87 days, has historically been high, indicating periods of inefficient working capital management. The overall picture suggests the management has struggled to deploy capital effectively and consistently.

The company's financial health shows signs of weakness. Borrowings increased significantly to ₹619 Cr in Mar 2023 before a slight reduction to ₹565 Cr in Mar 2024, indicating a reliance on debt. The Interest Coverage Ratio, a key measure of the ability to service debt, has deteriorated. It stood at 6.4x in Mar 2023 but fell to a low 2.4x in Mar 2024. This low ratio indicates a reduced buffer to cover interest payments from operational earnings. Furthermore, the company has a consistent policy of a 0% dividend payout. While this can imply reinvestment for growth, the poor and volatile returns on capital suggest that these retained earnings are not being used effectively to create shareholder value. The combination of notable debt, a weak interest coverage ratio, and no profit sharing with shareholders points to a weak financial prudence framework.

The ownership structure is a key strength. Promoter holding is very high and has remained stable at 75.26%, which signals strong confidence and long-term commitment from the management. Another significant positive is the trend in Domestic Institutional Investor (DII) holding. DIIs have substantially increased their stake, with their holding growing from 7.39% to 14.36% over the period shown. This indicates rising confidence from sophisticated domestic investors. However, this is contrasted by a clear negative trend in Foreign Institutional Investor (FII) holding. FIIs have been consistently reducing their stake, with their ownership declining from 7.34% to 1.38%. This divergence between FII and DII sentiment is notable. Despite the FII exit, the strong promoter backing and increasing DII conviction result in an overall good assessment for this category.

There are significant red flags concerning the company's accounting quality and the reliability of its reported earnings. The most prominent issue is the extreme volatility of net profit, which has fluctuated from a profit of ₹123 Cr (2021) to a loss of ₹251 Cr (2022) and then a minimal profit of ₹1 Cr (2024). Such wild swings question the sustainability and quality of earnings. Additionally, the profit and loss statement shows recurring negative 'Exceptional items' (-₹68 Cr in Mar 2023, -₹26 Cr in Mar 2024). When such items appear frequently, they may not be truly 'exceptional' and could be masking underlying operational issues. These factors combined create a high degree of uncertainty around the company's true financial performance.

The company has a clear and significant exposure to interest rate risk. As of March 2024, the company reported borrowings of ₹565 crore. The risk is amplified by the low Interest Coverage Ratio, which fell to 2.4x in March 2024. A low coverage ratio means that a smaller portion of operating profit is available to cover interest expenses, making the company's earnings more sensitive to any increase in interest rates or a decline in operating profit. A rise in borrowing costs could further strain profitability and cash flows. The provided data does not contain specific information to quantify foreign exchange exposure.